Myocardial infarction imposes a vast global burden, with ischemic heart disease causing over 106 million disability-adjusted life years annually. Modern data show a 7% 30-day mortality rate for STEMI despite reperfusion, and each 30-minute delay to treatment increases risk. This article details the clinical timelines, economic costs, and long-term outcomes that define the disease.
Key Takeaways
- 106.7 million disability-adjusted life years (DALYs) from ischemic heart disease in 2019 (burden including myocardial infarction)
- USD 17.3 billion direct medical costs for acute myocardial infarction and coronary heart disease in the U.S. in 2019
- USD 44.6 billion total economic costs for cardiovascular disease in the U.S. in 2016 (includes events such as myocardial infarction)
- 7% 30-day mortality for ST-segment elevation myocardial infarction (STEMI) in modern registries after reperfusion
- Approximately 10% of patients with myocardial infarction experience recurrent MI within 1 year
- 5–8% rate of in-hospital reinfarction among acute MI patients in contemporary observational cohorts
- 81% of cardiovascular drug approvals in 2021 were for lipid or platelet-targeting therapies relevant to post-MI management
- 2023 U.S. generic drug share is 92% by prescriptions (statin and antiplatelet generics drive affordability in post-MI therapy)
- FDA approval of tenecteplase for STEMI: accelerated thrombolysis option used when PCI is unavailable (approval-based adoption quantification varies; approval supports market availability)
- 62% of STEMI patients received reperfusion therapy within guideline-recommended time windows in selected registry settings (system-performance metric)
- Door-to-balloon median time was 90 minutes or less in benchmarking programs targeting 90-minute performance
- Every 10-minute improvement in door-to-balloon time is associated with lower short-term mortality (observed relationship quantified in registry analyses)
- Nearly 5% of U.S. adults have had heart attack (self-reported); used as a proxy for myocardial infarction prevalence in population surveys
- About 40% of adults in the U.S. have hypertension (a major risk factor for MI)
- In INTERHEART, 9 modifiable risk factors accounted for about 90% of the risk of acute myocardial infarction worldwide
Millions suffer myocardial infarction yearly, and faster reperfusion plus proper secondary prevention can greatly save lives.
Related reading
01 · Category
Disease Burden5 stats
01
106.7 million disability-adjusted life years (DALYs) from ischemic heart disease in 2019 (burden including myocardial infarction)
02
USD 17.3 billion direct medical costs for acute myocardial infarction and coronary heart disease in the U.S. in 2019
03
USD 44.6 billion total economic costs for cardiovascular disease in the U.S. in 2016 (includes events such as myocardial infarction)
04
Approximately 30% of people with coronary heart disease in the U.S. are estimated to have experienced a myocardial infarction
05
Approximately 7.9 million people worldwide suffer acute myocardial infarction each year (global incidence estimate)
Interpretation
Disease Burden Interpretation
From a disease burden perspective, ischemic heart disease accounted for 106.7 million DALYs in 2019 while the acute impact is mirrored by 7.9 million people worldwide experiencing acute myocardial infarction each year, underscoring a large and ongoing global toll.
02 · Category
Clinical Outcomes16 stats
01
7% 30-day mortality for ST-segment elevation myocardial infarction (STEMI) in modern registries after reperfusion
02
Approximately 10% of patients with myocardial infarction experience recurrent MI within 1 year
03
5–8% rate of in-hospital reinfarction among acute MI patients in contemporary observational cohorts
04
12-month mortality after myocardial infarction is about 15% in high-risk subgroups, reflecting prognostic stratification used in clinical risk models
05
About 20% of patients with myocardial infarction develop heart failure within 1–5 years
06
Time-to-treatment is critical: each 30-minute delay to reperfusion is associated with increased mortality after STEMI
07
Door-to-balloon time targets: ≤90 minutes for primary PCI in STEMI
08
Door-to-needle time target: ≤30 minutes for fibrinolysis in STEMI when PCI cannot be achieved promptly
09
Secondary prevention adherence: 70%+ of eligible MI patients should be on high-intensity statins per modern guideline targets; rates vary by system
10
About 30% of patients have persistent angina symptoms after MI due to residual ischemia
11
Approximately 50% of early recurrent symptoms after MI are linked to incomplete revascularization and microvascular dysfunction
12
2.2 million cardiac rehabilitation participants in the U.S. (annual participants) indicates substantial access to post-MI secondary prevention pathways (cardiac rehab enrollment).
13
33% relative reduction in major adverse cardiovascular events (MACE) with PCSK9 inhibitors compared with control in large outcome trials pooled in systematic review (effect size for post-ACS/secondary prevention populations).
14
7.3% absolute reduction in mortality with early invasive strategy vs conservative strategy in non-ST-elevation acute coronary syndrome, including NSTEMI populations (pooled estimate from major randomized evidence).
15
1–3% risk of recurrent MI within 30 days after discharge among patients treated with drug-eluting stents in contemporary PCI registries (30-day recurrent MI incidence).
16
0.8% per year incidence of new-onset heart failure after MI in population-based follow-up cohorts (annualized HF incidence).
Interpretation
Clinical Outcomes Interpretation
In the clinical outcomes after myocardial infarction, modern data show that despite reperfusion and guideline targets, about 7% die within 30 days after STEMI and roughly 20% go on to develop heart failure over 1 to 5 years, underscoring why post MI care and timely treatment are still central to improving real world prognosis.
03 · Category
Market & Therapies8 stats
01
81% of cardiovascular drug approvals in 2021 were for lipid or platelet-targeting therapies relevant to post-MI management
02
2023 U.S. generic drug share is 92% by prescriptions (statin and antiplatelet generics drive affordability in post-MI therapy)
03
FDA approval of tenecteplase for STEMI: accelerated thrombolysis option used when PCI is unavailable (approval-based adoption quantification varies; approval supports market availability)
04
High-intensity statins reduce risk of recurrent MI by about 24% vs lower-intensity (trial evidence used in guideline-based secondary prevention)
05
Aspirin + a P2Y12 inhibitor reduces risk of recurrent events after MI; clopidogrel addition reduces major adverse events by about 20% in CURE-like populations
06
Cardiac troponin is the primary biomarker: modern assays detect troponin levels at femtomolar-to-nanomolar clinical ranges enabling diagnosis of MI
07
In the U.S., PCSK9 inhibitors were priced around USD 14,000/year list price (widely reported; used for market access planning)
08
Rotational atherectomy is used in a minority of complex PCI procedures; in a large U.S. dataset it appeared in about 1–2% of PCI cases in recent years
Interpretation
Market & Therapies Interpretation
In the Market & Therapies space for post-MI care, lipid and platelet targeted drugs dominate approvals with 81% of 2021 cardiovascular launches and high impact secondary prevention stacks like aspirin plus a P2Y12 inhibitor, while continued affordability and access are reflected in 92% U.S. generic prescription share in 2023.
04 · Category
Health System Performance9 stats
01
62% of STEMI patients received reperfusion therapy within guideline-recommended time windows in selected registry settings (system-performance metric)
02
Door-to-balloon median time was 90 minutes or less in benchmarking programs targeting 90-minute performance
03
Every 10-minute improvement in door-to-balloon time is associated with lower short-term mortality (observed relationship quantified in registry analyses)
04
In US hospital systems, the proportion of eligible patients receiving aspirin within 24 hours after MI is commonly reported around 80%+ in quality measure reporting
05
In U.S. reporting, 76% of AMI patients receive smoking cessation advice at discharge (quality measure, varies by facility)
06
Tele-ECG adoption increased from near-zero to measurable coverage in pilot regions; in a randomized implementation study, prehospital ECG transmission improved time to reperfusion by 8 minutes on average
07
In-hospital statin prescription after MI in the U.S. has been reported at ~80% in quality improvement datasets
08
Cardiac rehabilitation referral rates after MI in the U.S. have been reported near 50% (quality and access benchmark)
09
One-way EMS transport times contribute to system delay; in a national analysis, median prehospital time for STEMI was about 80 minutes
Interpretation
Health System Performance Interpretation
Overall, U.S. and registry-based health system performance in myocardial infarction care shows that faster, better coordinated delivery matters, with door to balloon times reaching a median of 90 minutes or less and each 10 minute improvement tied to lower short term mortality, alongside many commonly tracked process measures clustering around the 50 to 80 percent range.
05 · Category
Epidemiology & Risk3 stats
01
Nearly 5% of U.S. adults have had heart attack (self-reported); used as a proxy for myocardial infarction prevalence in population surveys
02
About 40% of adults in the U.S. have hypertension (a major risk factor for MI)
03
In INTERHEART, 9 modifiable risk factors accounted for about 90% of the risk of acute myocardial infarction worldwide
Interpretation
Epidemiology & Risk Interpretation
From an epidemiology and risk perspective, about 5% of U.S. adults report a heart attack while roughly 40% have hypertension, and globally INTERHEART found that 9 modifiable risk factors explain around 90% of the risk of acute myocardial infarction, underscoring how major, preventable exposures drive MI burden.
06 · Category
Epidemiology2 stats
01
1 in 25 adults in the U.S. (about 4%) reported having had a heart attack (self-reported myocardial infarction) as of 2019–2022.
02
About 50% of out-of-hospital cardiac arrests in the U.S. are attributable to a cardiac cause, and myocardial infarction is a key driver of acute coronary syndromes leading to such arrests (share of cardiac vs non-cardiac arrest etiologies).
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, about 1 in 25 adults in the U.S. report having had a heart attack and with roughly half of out-of-hospital cardiac arrests linked to cardiac causes and myocardial infarction driving acute coronary syndromes, the burden of myocardial infarction appears both widespread and critically consequential.
07 · Category
Cost Analysis1 stats
01
$1.0 trillion is the estimated annual cost of cardiovascular disease in the U.S. in 2021 (includes costs associated with major cardiovascular events such as myocardial infarction).
Interpretation
Cost Analysis Interpretation
In Cost Analysis terms, the estimated $1.0 trillion annual burden of cardiovascular disease in the U.S. in 2021 underscores how major myocardial infarction related events drive enormous healthcare costs across the year.
08 · Category
Performance Metrics3 stats
01
≈90% of patients with acute MI are treated with an antiplatelet agent during hospitalization in U.S. practice (share receiving antiplatelet therapy during the index stay).
02
69% of eligible STEMI patients in a large contemporary registry received primary PCI (proportion treated with guideline-recommended primary PCI).
03
12% of STEMI patients in a contemporary registry did not receive reperfusion therapy (percentage untreated due to contraindications or system factors).
Interpretation
Performance Metrics Interpretation
Performance Metrics show that while about 90% of acute MI patients receive antiplatelet therapy during hospitalization, primary PCI is delivered to only 69% of eligible STEMI patients and 12% receive no reperfusion therapy, highlighting substantial gaps in timely guideline-recommended care.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Felix Zimmermann. (2026, February 13). Myocardial Infarction Statistics. Gitnux. https://gitnux.org/myocardial-infarction-statistics
MLA
Felix Zimmermann. "Myocardial Infarction Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/myocardial-infarction-statistics.
Chicago
Felix Zimmermann. 2026. "Myocardial Infarction Statistics." Gitnux. https://gitnux.org/myocardial-infarction-statistics.
Sources & references
47 datasets cited across this report · attribution is report-level
+33 additional datasets cited (not shown individually)